Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Verona Pharma plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Verona Pharma plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ebsworth David R | Director | 0Indirect | Oct 8, 2025 | 1 |
| Shah Mahendra | Director | 0 | Oct 8, 2025 | 1 |
| Sinha Vikas | Director | 0 | Oct 8, 2025 | 1 |
| Hahn Mark W | Chief Financial Officer | 0 | Oct 8, 2025 | 1 |
| Zaccardelli David | President and CEO | 0 | Oct 8, 2025 | 1 |
| Edwards Martin | Director | 0 | Oct 8, 2025 | 1 |
| Ackermann Christina | Director | 0 | Oct 8, 2025 | 1 |
| Ullman Anders | Director | 0 | Oct 8, 2025 | 1 |
| Cunningham Kenneth | Director | 0 | Oct 8, 2025 | 1 |
| Rickard Kathleen A. | Chief Medical Officer | 0 | Oct 8, 2025 | 1 |
| Deschamps Lisa | Director | 0 | Oct 8, 2025 | 1 |
| Brady James Aloysius | Director | 0 | Oct 8, 2025 | 1 |
| Austwick Michael | Director | 0 | Oct 8, 2025 | 1 |
| Fisher Andrew | General Counsel | 0 | Oct 8, 2025 | 1 |
| Poll Claire | General Counsel | 1,176,920Indirect | Feb 5, 2024 | 0 |
| OrbiMed Advisors LLC | Director | 3,777,778Indirect | May 15, 2023 | 0 |
| OrbiMed Capital GP VI LLC | Director | 3,777,778Indirect | May 15, 2023 | 0 |
| Gupta Rishi | Director | 3,777,778Indirect | May 15, 2023 | 0 |
| Blavatnik Len | 10% Owner | 55,911,648Indirect | Aug 17, 2022 | 0 |
| Access Industries Holdings LLC | 10% Owner | 55,911,648Indirect | Aug 17, 2022 | 0 |
| Access Industries Management, LLC | 10% Owner | 55,911,648Indirect | Aug 17, 2022 | 0 |
| AI Biotechnology LLC | 10% Owner | 55,911,648Indirect | Aug 17, 2022 | 0 |
| Sinclair Andrew | Director | – | Aug 10, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Deschamps LisaDirector | SSale | −9.46K | $13.14 | −$124.4K | −10.0%84.9K after | |
| Aug 5, 2025 (view filing) | Aug 1 | 4 days | Cunningham KennethDirector | SSale | −10.8K | $13.14 | −$142.0K | −11.9%79.8K after |